Accession Number:



Vault Nanoparticle Immunotherapy for Lung Cancer

Descriptive Note:

[Technical Report, Annual Report]

Corporate Author:

University of California

Personal Author(s):

Report Date:


Pagination or Media Count:



The object of this research is to develop a therapeutic strategy against lung cancer by utilizing novel vault bioparticles to deliver CCL21, an immunotherapeutic chemokine. Our hypothesis is that delivering CCL21 to the tumor, will make the entire repertoire of tumor antigens available in situ and thus increase the likelihood of an immune response and reduce the potential of phenotypic modulation. We have developed a bioparticle to deliver CCL21 that is based on the human vault particle. Vaults needed for initial animal studies CCL21-vaults and empty control vaults have been purified. We have secured ACURO approval for our animal studies and initial anti-tumor efficacy studies have been initiated in three animal models of lung cancer with the CCL21-vault as monotherapy. One model showed significant efficacy.

Subject Categories:

  • Medicine and Medical Research

Distribution Statement:

[A, Approved For Public Release]